In a previous paper we described the induction by x-irradiation or radiation-induced leukemia virus-inoculation of two classes of lymphoid T-cell neoplasms: The first class, designated T-cell lymphoblastoma (TCLB), consists of growth-factor-dependent eudiploid cells that home to the spleen and give rise to splenic tumors on injection into syngeneic mice; the second class, designated T-cell lymphoma (TCL), consists of growth-factor-independent aneuploid or pseudodiploid cells that give rise to local tumors at the site of subcutaneous injection. This paper describes the generation of a family of growth-factor-independent aneuploid or pseudodiploid TCL cells after the injection into the thymus of growthfactor-dependent diploid TCLI cells. In contrast to the donor TCLB cells, the resulting TCL cells could be cloned in semisolid medium, produced local tumors at the site of subcutaneous injection, and proliferated in a growth-factor-independent fashion in vitro. The induced growth-factor-independent TCL cells were chromosomally and phenotypically unstable and continued to evolve both in vivo and in vitro. After propagation in the thymus, the cells often showed stable translocations in addition to the evolving aneuploidy. We propose that the chromosome abnormalities induced during the proliferation of growth-factor-dependent TCLB cells in the thymus constitute a general mechanism by which neoplastic cells progress from growth-factor dependency to independency.
ABSTRACT
In a previous paper we described the induction by x-irradiation or radiation-induced leukemia virus-inoculation of two classes of lymphoid T-cell neoplasms: The first class, designated T-cell lymphoblastoma (TCLB), consists of growth-factor-dependent eudiploid cells that home to the spleen and give rise to splenic tumors on injection into syngeneic mice; the second class, designated T-cell lymphoma (TCL), consists of growth-factor-independent aneuploid or pseudodiploid cells that give rise to local tumors at the site of subcutaneous injection. This paper describes the generation of a family of growth-factor-independent aneuploid or pseudodiploid TCL cells after the injection into the thymus of growthfactor-dependent diploid TCLI cells. In contrast to the donor TCLB cells, the resulting TCL cells could be cloned in semisolid medium, produced local tumors at the site of subcutaneous injection, and proliferated in a growth-factor-independent fashion in vitro. The induced growth-factor-independent TCL cells were chromosomally and phenotypically unstable and continued to evolve both in vivo and in vitro. After propagation in the thymus, the cells often showed stable translocations in addition to the evolving aneuploidy. We propose that the chromosome abnormalities induced during the proliferation of growth-factor-dependent TCLB cells in the thymus constitute a general mechanism by which neoplastic cells progress from growth-factor dependency to independency.
The mechanism of evolution of T-cell lymphomas (TCL) within the thymus of systemically irradiated or radiation-induced leukemia virus (RadLV)-inoculated C57BL/6 (B6) mice is as yet unknown. Some models suggest that in the preneoplastic thymus there exists a continuing regenerative hyperplasia of cells leading to neoplasia, with the subsequent crowding out of the normal lymphocytes by neoplastic lymphoblasts (1) . This mechanism is based on the existence in treated mice of potentially neoplastic cells that would evolve to become neoplastic TCL cells by propagation in the thymus. Potentially neoplastic cells have been shown in systemically irradiated (2, 3) (5) . Furthermore, few properties of potentially neoplastic cells are known (6, 7) because they have neither been grown nor otherwise isolated from the putative organs of their in vivo residence.
We have propagated and cloned in culture a class of T lymphoblasts from the spleens and lymph nodes of irradiated or RadLV-inoculated mice long before these had developed a thymic lymphoma (8) . These neoplastic cells (T-cell lymphoblastoma; TCLB) precede the appearance of thymic lymphomas by 6-10 weeks. The isolation of these TCLB cells (8) propagation of immortalized T-cell blasts in the thymic microenvironment is necessary and may be sufficient for the generation of growth-factor-independent TCL cells.
MATERIALS AND METHODS
Tumor Cells. The induction of lymphomas by irradiation or virus-inoculation of B6 mice has been described (8) . Establishment of TCLB and TCL cell lines in culture, as well as their cloning in semisolid medium, has also been described (8) .
Intrathymic Inoculation of Cloned TCLB Cells. Mice injected intrathymically with TCLB cells develop rapidly growing thymic tumors. From the time enlarged thymuses could be palpated (thymus size, 300-400 mg; 16-18 days after injection) to the time of death (thymus size, 2-3 g), only 2-3 days elapsed. X-irradiated or virus-inoculated leukemic mice normally die 30-40 days after the first detection of thymic lymphomas by palpation. Mice that were inoculated intrathymically with an average of one TCLB cell and that died 20 days later with a thymic tumor of 3 g had experienced =32 cell doublings. This would indicate an average maximum doubling time of 16 hr. However, normal cells in the thymus are reported to have a high rate of proliferation and attrition (9) , suggesting that injected TCLB cells proliferate in the thymus at an even higher rate.
Cell Cloning in Methyl Cellulose. Cells were plated in 5-cm dishes in 0.8% methyl cellulose in Dulbecco modified Eagle's medium (DME medium) on top of a bottom layer of 1.1% agar in DME medium/10% fetal bovine serum. Routinely, 104 or 2 x 104 viable cells were plated per 5-cm dish.
Karyotype Analysis. Cells were incubated for 2 hr at 37°C in medium containing 0.025 ,ug of colcemid per ml. They were then centrifuged at 150 x g in a clinical centrifuge for 6 min. After aspiration of the medium, the pelleted cells were gently resuspended in 5 ml of 0.75 M KCl for 30 min during which time the cell suspension was mixed continually. Five A milliliters of freshly prepared fixative (methyl alcohol/glacial acetic acid, 2:1) was added to the cell suspension. The suspension was allowed to stand for 5 min at room temperature. After two changes of fixative, the cells were placed on glass slides for analysis. G-banding was analyzed after brief exposure to 0.5% trypsin and subsequent staining with Giemsa.
RESULTS
Thymic Versus Splenic Propagation of TCLB Cells. TCLB lines maintain their genotype when propagated for extended time periods in culture, when cloned in methyl cellulose in the presence of exogenous growth factor, and on splenic propagation in vivo (8) . Intraperitoneal inoculation of 104 TCLB cells (female cell line 18-28-4SPL) into male syngeneic B6 mice induced splenic tumors of donor cell origin. (LD50 = 5000 cells for i.p. inoculation in 6-week-old B6 mice.) Upon return of these cells to culture no differences were detected between the inoculated cells and the cells that had been passaged through the spleen. The cells were growthfactor dependent, growth-factor secreting, autostimulating, and eudiploid. The phenotype of the specific line used (TL-1-2-4-, TdT-, Lyt-1+2-3-, Thy-1+, IL-2+) was stable through in vivo (splenic) passage (8) . Furthermore, expression of a panel of oncogenes by TCLB cells did not change after in vitro cloning or in vivo splenic propagation (unpublished observations).
In contrast, inoculation of TCLB cells into the thymus gave rise to significant genotypic and phenotypic changes in the cells. Male B6 mice in groups of 10 were inoculated intrathymically with 200, 20, or (on the average) 1 female TCLB cells. (LD50 10 cells for intrathymic inoculation into 6-week-old B6 mice.) From 16 to 18 days after inoculation, the mice developed large (2-3 g) thymic tumors that were explanted in vitro, grown for five to eight transfers (12-20 days; 18-30 cell doublings), and studied by karyotyping, cloning in methyl cellulose, growth-factor dependency, growth in vivo, interleukin 2 production, and cell markers. The genotypic and phenotypic changes that were induced by thymic propagation of TCLB cells are described below.
Cell Cloning in Semisolid Medium of Derived TCL Cells. After thymic propagation of the eudiploid TCLB cells, the average DNA content per cell increased significantly. Thymus-derived TCL cells (107) in mass culture were stained with the DNA-binding fluorescent dye mithramycin. The DNA content per cell was estimated by flow microfluorimetry and was compared to the DNA content of similarly stained TCLB cells. Mithramycin fluorescence intensity is proportional to DNA content (10, 11) . Cell cycle analysis and fluorescence intensity of the cells in G1 phase indicated that mass cultures of TCL cells that were derived by intrathymic inoculation of TCLB cells contained 4.5-6% more DNA than the precursor TCLB cells, as is shown in Fig. 1B TCLB cell (Fig. 2) . Of nine single cell clones of the D1 tumor that were grown in methyl cellulose and analyzed, seven contained the translocation in chromosome 4. The source of the translocated segment has not yet been determined. Like other tumors that were derived by injection of TCLB cells into the thymus, the TCL mass culture D1 also displayed considerable chromosome instability over and above the stable translocation in chromosome 4 (Table 2; Fig. 2 ). Chromosome instability and the induction of aneuploidy and translocations have been observed after inoculation of two other independently isolated TCLB cell lines into the thymus of mice (not shown).
Once explanted and cloned, the derived TCL cells continued to show chromosomal instability in culture. Recloning of Fig. 2 ). Data for cell clones D1-1 and D1-9 refer to cells that were twice cloned in methyl cellulose, then grown in mass culture, and prepared for karyotyping. All cells were of donor (female) origin. Table 2. the cells in soft agar revealed new aneuploid or pseudodiploid segregants from a single clone. This was also the case for the D1 tumor cells when passaged in culture ( Fig. 2 ; Table 2). The instability of the derived TCL cells is notable in comparison to the phenotypic and genotypic stability in vivo and in vitro of the eudiploid TCLB cells. It also contrasts with the stability of the TCL cells trisomic for chromosome 15, which were isolated from frank thymic lymphomas after a 3-5 month period of latency (8) .
Tumorigenic Properties of Derived TCL Cells. After proliferation of TCLB cells in the thymus, derived TCL cells produced tumors at the site of subcutaneous injection. Mass cultures were established from thymic tumors induced by intrathymic inoculation of (an average of) one TCLB cell. The resulting TCL cells were cloned in methyl cellulose and 10 clones were picked at random and grown. Cells (104) of clones D1-1 to Dl-10 were injected subcutaneously into groups of 6-week-old male mice. The cloned derived TCL cells gave rise to walnut-sized subcutaneous tumors at the site of injection in 100% of injected mice in 2 weeks. In control groups, no local tumors developed in mice similarly injected with 104 TCLB cells, although 9 out of 10 of the control mice developed splenic tumors in 5-6 weeks.
DISCUSSION
We have previously shown (8) that x-irradiated mice or mice that had been inoculated with RadLV often harbor two stable distinct T-cell neoplasms, one composed of growth-factor-dependent eudiploid TCLB cells that did not grow under the skin of mice or clone in semisolid medium, and a thymic neoplasm composed of growth-factor-independent, monoclonal, trisomic TCL cells, which generated local subcutaneous tumors at the site of inoculation and could be quantitatively cloned in semisolid medium. We have designated the corresponding tumors T-cell neoplasms of phase I (lymphoblastomas), and phase III (lymphomas), respectively. (8, (15) (16) (17) may therefore be the end result of the process described here-namely, the generation of organ-specific genetic havoc that is induced by the thymic microenvironment. In contrast to the genetic instability of the experimentally derived phase II TCL cells, thymic lymphomas that are induced by x-irradiation, virus-inoculation, or by chemicals have been reported to be composed of stable trisomic cells (12) (13) (14) (15) (16) (17) (18) (19) ; the class of chromosomally unstable phase II TCL cells has not been described. Phase II thymic TCL cells may not have been observed previously because a cell transplantation step was used in the preparation of the TCL cells for karyotyping (14) (15) (16) (17) . Such transplantation selects for the growth-factor-independent trisomic TCL cells. By avoiding the transplantation step, we have found that many (>60%) xray-induced and virus-induced thymic TCL cells are composed of genetically unstable, phase II lymphoma cells. Neoplastic T cells of phase II are often found in thymic lymphomas of x-irradiated and virus-inoculated mice, and thus are not an experimental artefact (unpublished results).
It is not known how the thymic microenvironment induces chromosomal abnormalities in proliferating TCLB cells. One can envisage a positively acting mechanism (e.g., by means of a thymus-specific growth factor) or a negatively acting mechanism: forced proliferation in the absence of growth factor(s) may induce unbalanced growth and chromosome abnormalities. In addition, the replication of mink-cell focusinducing thymotropic virus may contribute to the observed genetic havoc. Even if the first aberrant mitoses are triggered by the thymic microenvironment, it is striking that they continue when the cells are removed from it. What is imposed or derepressed in the thymus is not a transient response to environmental conditions but rather a long-term genetic instability. The mechanism of thymus-induced chromosome abnormalities should be experimentally testable now that TCLB cells that are susceptible to the thymic microenvironment are available in vitro.
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